CACLP - The largest IVD Expo & Conference

Lucira Health Q4 Revenues Jump on Demand for At-Home Molecular COVID-19 Tests

Industry news | 14 March, 2022 | CACLP

Original from: Genomeweb


Lucira Health on Thursday reported a huge year-over-year surge in revenues for the fourth quarter of 2021 on ramped-up manufacture and sale of the company's molecular at-home COVID-19 tests.


For the three-month period ended Dec. 31, Lucira's revenues jumped to $61.1 million from $269,000 in the same quarter the year before. Driving the increase were sales of the company's over-the-counter Lucira Check-It COVID-19 test kit, which received US Food and Drug Administration Emergency Use Authorization in April 2021, and its prescription Lucira COVID-19 All-In-One test kit, which received FDA authorization in late 2020. Analysts had, on average, expected $40.7 million in Q4 revenues.


"Lucira's strong fourth quarter is indicative of the inflection point the company is experiencing in its growth," Lucira President and CEO Erik Engelson said in a statement. "The strong financial performance was a result of a rise in manufacturing output against consistently high demand in the quarter."


Lucira's net loss in the quarter fell to $7.8 million, or $.20 per share, from a year-ago net loss of $17.2 million, or $6.70 per share, staying well below the Wall Street loss-per-share consensus estimate of $.55. The prior year's loss per share reflects the lower number of the company's shares outstanding ahead of its February 2021 initial public offering: Lucira used 2.6 million shares to calculate net loss per share for Q4 of 2020 but 39.0 million shares to do the same for Q4 of 2021.


R&D spending in the fourth quarter was up 7 percent to $9.1 million from $8.5 million in the year-ago quarter, while SG&A costs jumped nearly fivefold to $11.6 million from $2.4 million year on year.


At the end of 2021, Lucira had cash reserves of $106.0 million.


For full-year 2021, Lucira's revenues climbed to $93.1 million from $269,000 in 2020, beating the Wall Street consensus estimate of $73.7 million. 


The Emeryville, California-based company's net loss for 2021 arrived at $64.8 million, or $1.86 per share, compared with $37.3 million, or $15.58 per share, the year before.


R&D expenses for the year jumped 62 percent to $39.8 million from $24.6 million in 2020, while SG&A costs rocketed to $35.5 million from $5.6 million year over year.


Looking ahead, Lucira said it expects revenues for the first quarter of 2022 in the range of $80.0 million to $85.0 million, and full-year revenues greater than $450.0 million. 


In morning trading on the Nasdaq, Lucira's shares were up 14 percent at $3.86.


Source: Lucira Health Q4 Revenues Jump on Demand for At-Home Molecular COVID-19 Tests

Filed under:
Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference